Xingqi eye drug cyclosporine eye drops (II.) entered the medical insurance directory

Shanghai Securities News China Securities Network News From January 1, 2022, the new version of the national medical insurance drug catalogue was officially implemented. Among them, 74 new drugs outside the catalog, Xingqi eye drug cyclosporine eye drops (II) is the only ophthalmic product among the 74 new successful drugs, with a people-friendly price of 165 yuan for patients.

It is reported that the drug can promote the secretion of tear fluid in patients with dry eye disease, suitable for patients with reduced tear production caused by eye inflammation related to dry corneal sygchens, is the first and only cyclosporine ophthalmic preparation for dry eye treatment in China, and is currently a major weapon for domestic dry eye treatment, escorting dry eye patients.

Dry eye is currently the most common ocular surface disease that affects vision and quality of life. According to the definition of the "Chinese Dry Eye Expert Consensus (2020)", dry eye is a chronic ocular surface disease caused by multiple factors, which is caused by the instability of the tear film or the imbalance of the microenvironment of the ocular surface caused by abnormal quality, quantity and kinetics of tear fluid, which can be accompanied by ocular surface inflammation, tissue damage and nerve abnormalities, resulting in a variety of discomfort symptoms and/or visual dysfunction of the eye. According to foreign epidemiological reports, the prevalence of dry eye in people aged 30 to 40 years is 20%, and the prevalence of people over 70 years old is as high as 36.1%, and women are significantly higher than men. The incidence rate in China is about 32.1%, and some eye clinics account for nearly 60% of dry eye patients, and dry eye disease has increased year by year in recent years, and shows a trend of younger age.

It is understood that zirun 0.05% cyclosporine eye drops (II.) independently developed by Xingqi Eye Medicine has both the effect of treating dry eyes and has an anti-inflammatory effect, cyclosporine not only blocks the vicious cycle of inflammation by inhibiting T cell activation and the release of inflammatory factors, but also inhibits the apoptosis of lacrimal gland acinar cells, directly promotes the release of neurotransmitters, improves tear nerve feedback, and promotes tear secretion. It can also inhibit goblet cell apoptosis, increase intracellular mucin reserves, and directly stimulate mucin secretion. The "triple effect" determined that the drug opened a new era in the treatment of dry eyes.

The product is a micro-emulsion dosage form, the particle size is smaller and more uniform, using a series of innovative processes such as nano-scale microemulsion preparations, which realizes the leapfrog upgrading from ordinary emulsions to colorless transparent eye drops, with a more uniform particle size, a more stable dosage form, and a more comfortable point eye, which not only makes the drug point eye more comfortable and tolerant, but also increases the stability of the preparation. At the same time, the product does not add preservatives, bringing a safer, more effective and comfortable treatment experience for the majority of patients with dry eyes in China, especially patients with moderate to severe dry eyes and immune-related dry eyes. (Chen Zhiqiang)